Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir prophylaxis for CMV-seropositive adult allogeneic HSCT recipients
ChiCTR2300078877Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of letermovir in cytomegalovirus disease (CMV), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Clinically significant incidence of CMV infection within 14 weeks after transplantation. Started Dec 2023; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ChiCTR2300078877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078877.